BTK and B-cell chronic lymphocytic leukemia: Ibrutinib emerged as the first small-molecule inhibitor to selectively block the activity of the Bruton tyrosine kinase (BTK) [5,6,7], with excellent efficacy in CLL proved by no less than five clinical trials.